Diabetes mellitus is considered as a common comorbidity in chronic heart failure patients and leads to poorer outcomes. A SHIFT analysis presented at the Heart Failure Congress 2014, Athens, May 2014 concluded that the primary composite end pointof cardiovascular death and hospitalization for worsening heart failure was reduced similarly by ivabradine in patients with and without diabetes mellitus (P for interaction=0.86), as was hospitalization for heart failure. This confirmed that the efficacy and safety of ivabradine are similar in diabetic and non-diabetic patients.1

1. Komajda M, Tavazzi L, Swedberg K, et al. Efficacy and safety of ivabradine in patients with chronic heart failure and diabetes: an analysis from the SHIFT trial. European Society of Cardiology.2014;16(Suppl. 2):42.Abstract P227